Therapeutic Drug Monitoring: The Way Towards Individualized Secukinumab Dosing In Psoriasis

With the introduction of new biologics for psoriasis, achieving optimal response is a realistic goal. However, real life data reveal that response varies from optimal to non-response and loss of response urging physicians to explore off-label intensification. Therapeutic drug monitoring (TDM) could prevent these 'blind' modifications by guiding physicians in their clinical decision-making. In order to perform TDM, two fundamental requirements are 1) assay accessibility and 2) knowledge about an optimal therapeutic window.